ARTICLE SUMMARY:
With a mission of making cancer care more tolerable to patients, Luminate has advanced device products for the prevention of chemotherapy-induced hair loss and peripheral neuropathy. It’s now overhauling the provision of care itself, with a technology-enabled solution for the delivery of oncology therapeutics at home.
Galway-based Luminate Medical is reshaping the landscape of cancer care with a mission to make the journey more tolerable for patients. With innovative medical devices designed to prevent chemotherapy-induced hair loss and peripheral neuropathy, the company is now setting its sights on transforming the delivery of oncology care itself—introducing technology-driven solutions that enable at-home cancer treatment.
In 2023 when we first spoke with Aaron Hannon, CEO and co-founder of Luminate Medical, the company had two groundbreaking devices in development. The first, Lily, is a portable helmet designed to deliver microvascular compression therapy, helping to prevent the hair loss that often accompanies aggressive chemotherapy. Lily is currently part of a clinical trial in the US called PREVAIL, which is expected to wrap up by the end of this year. The second product, Lilac, is a wearable glove and boot set that applies controlled low-level compression to the hands and feet to protect peripheral nerves, preventing peripheral neuropathy during and shortly after chemotherapy. This product is actively being studied in a randomized trial across 12 sites in the US and Ireland.
